Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacological inhibition of PMS2 induces MMR deficiency and response to immune checkpoint blockade.

Cancer discovery·2026
Same author

Enhanced activity of apramycin and apramycin-based combinations against Mycobacteroides abscessus.

The Journal of antimicrobial chemotherapy·2025
Same author

Correction to "Sebetralstat (KVD900): A Potent and Selective Small Molecule Plasma Kallikrein Inhibitor Featuring a Novel P1 Group as a Potential Oral On-Demand Treatment for Hereditary Angioedema".

Journal of medicinal chemistry·2025
Same author

De Novo Design and Asymmetric Synthesis of a <i>C</i>-1/2 Benzodioxin Fused Glycoside Analogue of Lincomycin.

Organic letters·2025
Same author

Correction to "A Novel Use of Gentamicin in the ROS-Mediated Sensitization of NCI-H460 Lung Cancer Cells to Various Anticancer Agents".

ACS chemical biology·2025
Same author

Enhanced Activity of Apramycin and Apramycin-Based Combinations Against <i>Mycobacteroides abscessus</i>.

bioRxiv : the preprint server for biology·2025

Related Experiment Video

Updated: May 13, 2026

Split Hybridization Probe Utilizing a DNA Fluorescent Light-up Aptamer as a Signal Reporter for Sequence-Specific Nucleic Acid Analysis
07:10

Split Hybridization Probe Utilizing a DNA Fluorescent Light-up Aptamer as a Signal Reporter for Sequence-Specific Nucleic Acid Analysis

Published on: July 8, 2025

Improving the affinity of SL0101 for RSK using structure-based design.

Roman M Mrozowski1, Rajender Vemula, Bulan Wu

  • 1Department of Pathology, Microbiology & Immunology, Vanderbilt University, Nashville, TN.

ACS Medicinal Chemistry Letters
|March 23, 2013
PubMed
Summary

Researchers developed a novel RSK inhibitor analogue with significantly improved binding affinity for cancer drug development. While more potent in vitro, further optimization is needed for in vivo efficacy, focusing on membrane permeability.

Keywords:
4″-di-O-acetyl-a-L-rhamnopyranoside)Kaempferol 3-O-(3″RSKSL0101kinase inhibitorp90 ribosomal S6 kinase

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow
08:58

Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow

Published on: October 17, 2025

Related Experiment Videos

Last Updated: May 13, 2026

Split Hybridization Probe Utilizing a DNA Fluorescent Light-up Aptamer as a Signal Reporter for Sequence-Specific Nucleic Acid Analysis
07:10

Split Hybridization Probe Utilizing a DNA Fluorescent Light-up Aptamer as a Signal Reporter for Sequence-Specific Nucleic Acid Analysis

Published on: July 8, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow
08:58

Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow

Published on: October 17, 2025

Area of Science:

  • Biochemistry
  • Medicinal Chemistry
  • Cancer Biology

Background:

  • Aberrant activity of Ser/Thr protein kinase, RSK, is linked to cancer progression and metastasis, identifying it as a key therapeutic target.
  • The natural product SL0101 is a selective RSK inhibitor but exhibits limited in vivo efficacy due to low affinity (Ki = 1 μM) and a short half-life (<30 min).

Purpose of the Study:

  • To design and synthesize novel RSK inhibitor analogues with enhanced affinity and efficacy compared to SL0101.
  • To investigate the structure-activity relationship of SL0101 analogues for improved drug development.

Main Methods:

  • Utilized the crystallographic model of SL0101 bound to the RSK2 N-terminal kinase domain to guide analogue design.
  • Synthesized a series of SL0101 analogues, including one with a 5″-n-propyl modification on the rhamnose sugar.
  • Assessed in vitro kinase inhibition assays and cell proliferation assays using human breast cancer (MCF-7) and normal breast (MCF-10A) cell lines.

Main Results:

  • Identified a 5″-n-propyl analogue demonstrating >40-fold improved binding affinity for RSK compared to SL0101 in vitro.
  • The analogue selectively inhibited proliferation of MCF-7 cells over MCF-10A cells, consistent with SL0101.
  • Observed only a two-fold improvement in antiproliferative efficacy in MCF-7 cells, potentially limited by membrane permeability.

Conclusions:

  • The 5″-n-propyl analogue represents a significant advancement in RSK inhibitor design, offering substantially enhanced binding affinity.
  • Further structural modifications are necessary to improve membrane permeability and overall in vivo efficacy for therapeutic applications.
  • The improved affinity provides a valuable foundation for developing future RSK-targeted cancer therapies.